Fulgent Genetics (FLGT)

• Market cap: $630M
• 1 day: -1.43%
• 5 days: -4.26%
• 1 month: 1.97%
• 3 months: 21.85%
• 6 months: 5.67%
• Year to date: 12.32%
• 1 year: 6.70%
• 5 years: 25.39%
• 10 years: 125.38%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Employees: 1,313

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

641% more call options, than puts

Call options by funds: $6.93M | Put options by funds: $935K

26% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 50

2.87% less ownership

Funds ownership: 55.63% [Q4 2024] → 52.76% (-2.87%) [Q1 2025]

7% less funds holding

Funds holding: 188 [Q4 2024] → 174 (-14) [Q1 2025]

12% less capital invested

Capital invested by funds: $314M [Q4 2024] → $275M (-$39M) [Q1 2025]

31% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 36

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $23 11% upside
• Avg. target: $24 16% upside
• High target: $25 21% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

Piper Sandler David Westenberg	11% upside $23	Neutral Maintained	6 May 2025
Raymond James Andrew Cooper	21% upside $25	Outperform Reiterated	5 May 2025